The risks of in-hospital complications and mortality at 30 days were significantly higher in patients with severe aortic ...

WASHINGTON, DC — New European registry data on transcatheter aortic-valve replacement (TAVR) in patients at lower surgical risk than those studied in the pivotal randomized trials offers the ...

Washington, D.C. – May 2, 2025 – New analysis from the EARLY TAVR trial showed patients between the age of 65 and 70 years old derived the most benefits of a strategy of early intervention with ...

Patients with heart failure who took dapagliflozin, a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, after undergoing transcatheter aortic valve replacement (TAVR) were significantly less likely ...

Please provide your email address to receive an email when new articles are posted on . Transcatheter aortic valve replacement for younger adults with severe aortic stenosis rose nearly ninefold from ...

PARIS -- Patients with questionable suitability for transcatheter aortic valve replacement (TAVR) in fact fared worse in the short term after the catheter-based procedure than after surgery, the ...

Patients with heart failure who took dapagliflozin, a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, after undergoing transcatheter aortic valve replacement (TAVR) were significantly less likely ...

The Structural Heart Program team at McGovern Medical School at The University of Texas Health Science Center at Houston (UTHealth) is among the first in the country to investigate the safety and ...

- Transcatheter aortic valve replacement (TAVR) procedure treats people with symptomatic, severe aortic stenosis who are at high or extreme risk for open-heart surgery - With Portico approval, Abbott ...

While many people fear a cancer diagnosis above all else, clinical data reveals that symptomatic aortic stenosis, a severe ...

Medtronic will invest $90M in Anteris Technologies for DurAVR TAVR device development, contingent on a $200M IPO.